Rigel Pharma (RIGL) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 --0%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.9 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- UBS Upgrades Eaton Corporation (ETN) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
